TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA
Brief Summary: The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.


Options:
A: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
C: Arm Label: Abatacept, 125 mg, plus methotrexate, 2.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Methotrexate, 2.5 mg, plus abatacept placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Abatacept placebo | Arm Label: Abatacept, 125 mg, plus methotrexate placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Methotrexate placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate placebo, Abatacept, 125 mg, plus methotrexate, 2.5 mg | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate, 2.5 mg, Methotrexate, 2.5 mg, plus abatacept placebo | Intervention Type: DRUG; Name: Abatacept placebo; Assigned to Arm(s): Methotrexate, 2.5 mg, plus abatacept placebo | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate placebo
D: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Intervention Improvement Telemedicine Study
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have \> 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Electronic Pill Bottle tracking | Arm Label: Feedback group; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Pill Bottle tracking, Behavioral: Adherence Messaging | Arm Label: Adherence partner group; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Pill Bottle tracking, Behavioral: Social Influence | Arm Label: Adherence partner along with feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Pill Bottle tracking, Behavioral: Adherence Messaging, Behavioral: Social Influence | Intervention Type: BEHAVIORAL; Name: Electronic Pill Bottle tracking; Assigned to Arm(s): Adherence partner along with feedback, Adherence partner group, Control, Feedback group | Intervention Type: BEHAVIORAL; Name: Adherence Messaging; Assigned to Arm(s): Adherence partner along with feedback, Feedback group | Intervention Type: BEHAVIORAL; Name: Social Influence; Assigned to Arm(s): Adherence partner along with feedback, Adherence partner group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminders of medicines intake | Intervention Type: BEHAVIORAL; Name: SMS reminders of medicines intake; Assigned to Arm(s): Intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitors and pharmacy management; Type: EXPERIMENTAL; Interventions: Other: Telemonitors and pharmacy management | Intervention Type: OTHER; Name: Telemonitors and pharmacy management; Assigned to Arm(s): Telemonitors and pharmacy management
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist CVD | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacist CVD; Assigned to Arm(s): Arm 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Brief Summary: Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.


Options:
A: Arm Label: Sertindole; Type: EXPERIMENTAL; Interventions: Drug: Sertindole | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Sertindole; Assigned to Arm(s): Sertindole | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine
B: Arm Label: 600 mg/day quetiapine (Group B); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: 1200 mg/day quetiapine (Group A); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 1200 mg/day quetiapine (Group A) | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 600 mg/day quetiapine (Group B)
C: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Brief Summary: Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.


Options:
A: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
B: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperdal | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Risperdal; Assigned to Arm(s): Active

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Brief Summary: This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): N/A
D: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Brief Summary: This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Brief Summary: This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.


Options:
A: Arm Label: Standard medical treatment plus albumin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diuretics plus human albumin | Arm Label: Standard medical treatment; Type: OTHER; Interventions: Drug: Diuretics (standard medical treatment) | Intervention Type: DRUG; Name: Diuretics plus human albumin; Assigned to Arm(s): Standard medical treatment plus albumin | Intervention Type: DRUG; Name: Diuretics (standard medical treatment); Assigned to Arm(s): Standard medical treatment
B: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Albumin plus midodrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: albumin, Drug: Midodrine | Arm Label: salin solution plus pills; Type: PLACEBO_COMPARATOR; Interventions: Drug: albumin, Drug: Placebo | Intervention Type: DRUG; Name: albumin; Assigned to Arm(s): Albumin plus midodrine, salin solution plus pills | Intervention Type: DRUG; Name: Midodrine; Assigned to Arm(s): Albumin plus midodrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): salin solution plus pills

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Brief Summary: This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
D: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea - Randomised, Double-blind, Placebo-controlled Trial
Brief Summary: When patients in hospitals receive antibiotics they often develop diarrhoea. The consequences may be grave for the patient. Thus far, no preventive measure is available. The investigators hypothesize that the apathogenic yeast Saccharomyces boulardii, administered in addition to the antibiotic, may prevent episodes of diarrhoea or may lead to less pronounced diarrhoea. To test this hypothesis, the investigators are carrying out a clinical trial in 1520 adult patients in several hospitals.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: BIO-K+ CL-1285; Type: ACTIVE_COMPARATOR; Interventions: Other: BIO-K+ CL-1285® | Arm Label: BIO-K+ CL-1285® & placebo; Type: OTHER; Interventions: Other: BIO-K+ CL-1285®, Other: Placebo | Intervention Type: OTHER; Name: BIO-K+ CL-1285®; Assigned to Arm(s): BIO-K+ CL-1285, BIO-K+ CL-1285® & placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): BIO-K+ CL-1285® & placebo, Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
D: Arm Label: Saccharomyces boulardii; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saccharomyces boulardii | Arm Label: Microcristallin cellulose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Microcristallin cellulose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia
Brief Summary: The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.


Options:
A: Arm Label: Riboflavin 0.1% eyedrops every 5 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Arm Label: Riboflavin 0.1% eyedrops every 2 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes | Intervention Type: DEVICE; Name: UVX light; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes
B: Arm Label: total removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (total removal) | Arm Label: partial removal; Type: OTHER; Interventions: Procedure: collagen cross-linking procedure (partial removal) | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (total removal); Assigned to Arm(s): total removal | Intervention Type: PROCEDURE; Name: collagen cross-linking procedure (partial removal); Assigned to Arm(s): partial removal
C: Arm Label: Cross-linking with iontophoresis; Type: EXPERIMENTAL; Interventions: Device: Cross-linking with iontophoresis | Arm Label: Standard corneal cross-linking; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard corneal cross-linking | Intervention Type: DEVICE; Name: Cross-linking with iontophoresis; Assigned to Arm(s): Cross-linking with iontophoresis | Intervention Type: DEVICE; Name: Standard corneal cross-linking; Assigned to Arm(s): Standard corneal cross-linking
D: Arm Label: Epithelium on; Type: ACTIVE_COMPARATOR; Interventions: Drug: CXL | Arm Label: Epithelium off; Type: ACTIVE_COMPARATOR; Interventions: Drug: CXL | Intervention Type: DRUG; Name: CXL; Assigned to Arm(s): Epithelium off, Epithelium on

Answer: A